Benzinga · Feb 25, 2026
EN
NASDAQ · ENVB
Enveric Biosciences, Inc.
Healthcare · Biotechnology
$1.42
Down-$0.04 (-2.74%)
Updated Sep 12, 2026, 2:08 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.25M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $1.17 – $13.25
- Volume
- 38.75K
- Avg. volume
- 85.35K
Price performance
ENVB price history
1M range · 0 trading sessions · Daily adjusted prices
ENVB does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ENVB news
The latest Smart Investors Daily articles mentioning ENVB.
Stock researchCompany · Overview
ENVB research
Overview
Company profile and research snapshot.
Company profile
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 6, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 1, 2022 | Alliance Global Partners | Buy | — |
| Mar 8, 2022 | Aegis Capital | Hold | — |
| Jul 8, 2021 | Aegis Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 25, 2026
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested
Gilgamesh withdraws patent challenge against Enveric, leaving the key psilocybin patent uncontested.
Benzinga · Feb 25, 2026
Enveric Biosciences Announces Withdrawal Of Petition Against Patent; Co Says There Are 'No Remaining Challenges' Pending Against Patent
Benzinga · Feb 19, 2026
Enveric Biosciences shares are trading higher after the company announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
